691 related articles for article (PubMed ID: 26350229)
1. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
2. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.
Azuma K; Obata R; Nomura Y; Tan X; Takahashi H; Yanagi Y
Retina; 2016 Nov; 36(11):2158-2165. PubMed ID: 27258669
[TBL] [Abstract][Full Text] [Related]
3. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
[TBL] [Abstract][Full Text] [Related]
5. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
[TBL] [Abstract][Full Text] [Related]
6. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Hara C; Sawa M; Sayanagi K; Nishida K
Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
[TBL] [Abstract][Full Text] [Related]
7. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
[TBL] [Abstract][Full Text] [Related]
8. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
Komuku Y; Iwahashi C; Gomi F
Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
[TBL] [Abstract][Full Text] [Related]
10. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
11. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
Ijiri S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
[TBL] [Abstract][Full Text] [Related]
12. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
Lee JH; Lee WK
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
[TBL] [Abstract][Full Text] [Related]
14. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
15. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Kawasaki R; Sekiryu T; Okada AA; Iida T
Am J Ophthalmol; 2015 Apr; 159(4):627-33. PubMed ID: 25555799
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
Jeong S; Sagong M
Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Br J Ophthalmol; 2015 Sep; 99(9):1284-8. PubMed ID: 25777816
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
[No Abstract] [Full Text] [Related]
19. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]